Terms ending in 2038
Universitätsklinikum Hamburg-Eppendorf
Every in-force patent on Universitätsklinikum Hamburg-Eppendorf's record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,464,833 | Methods for Treating or Preventing Tissue Adhesions In force · High confidence | Neutrolis, Inc. | In force | High confidence | |
| US 11,013,755 | Microrna 19A/19B for Use in Treating a Pathological Condition Associated with Bone Loss or Reduced Muscle Function In force · High confidence | Universitatsklinikum Hamburg-Eppendorf | In force | High confidence | |
| US 11,793,828 | Microrna 19A/19B for Use in Treating a Pathological Condition Associated with Bone Loss or Reduced Muscle Function In force · High confidence | Universitätsklinikum Hamburg-Eppendorf | In force | High confidence | |
| US 10,696,956 | Engineered Dnase Enzymes and Use in Therapy In force · Medium confidence | Neutrolis, Inc. | In force | Medium confidence | |
| US 10,801,019 | Engineered Dnase Enzymes and Use in Therapy In force · Low confidence | Neutrolis, Inc. | In force | Low confidence | |
| US 11,046,942 | Dnase Therapy for Intravascular Accumulation of Extracellular DNA In force · Low confidence | Neutrolis Inc. | In force | Low confidence | |
| US 11,046,943 | Dnase Therapy for Intravascular Accumulation of Extracellular DNA In force · Low confidence | Neutrolis Inc. | In force | Low confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Universitätsklinikum Hamburg-Eppendorf.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.